DermBiont, Inc. news
BOSTON, Jan. 8, 2021 /PRNewswire-PRWeb/ -- DermBiont, a clinical-stage biotechnology company developing targeted topical therapeutics, - announced today that its Phase 2a clinical trial with its investigational drug product, DBI-001, in atopic dermatitis, has demonstrated decreases in the abundance in S. aureus, improvement in signs and symptoms
BOSTON--(BUSINESS WIRE)-- DermBiont, Inc., a clinical-stage biotechnology company developing targeted topical therapeutics that address the root causes of skin diseases, announced today that it has raised a $28 million Series A2 financing in parallel with the acquisition of clinical-stage biotechnology company Chromaderm, which is developing a topical inhibitor of melanin pr
BOSTON, Jan. 8, 2021 /PRNewswire-PRWeb/ -- DermBiont, a clinical-stage biotechnology company developing targeted topical therapeutics, announced today that its phase 2b clinical trial with its investigational drug product, DBI-001, for the treatment of tinea pedis resulted in statistically significant decreases in the abundance in T. ru
BOSTON, MA, October 21, 2020 – DermBiont, Inc., a clinical stage precision dermatology company targeting skin diseases at their root cause has expanded its pipeline and therapeutic modalities with the acquisition of SeylanMED, Inc.
“This strategic acquisition delivers multi-factorial value,” said Karl Beutner, MD, PhD, Co-founder, CEO, and CMO of DermBiont. “It expands our therapeutic pipeline with a first-in-class, targeted topical small molecule as well